Severe Asthma ToolkitSevere Asthma Toolkit
HomeAboutSpecific PopulationsRegistriesContributorsContact
Twitter
  • What is Severe Asthma?
    • Overview
    • Definition
    • Prevalence & Burden
    • Pathophysiology
    • Symptoms
    • Severe Asthma Attacks / Exacerbations / Flare-ups
    • Asthma Phenotypes
  • Diagnosis & Assessment
    • Overview
    • Diagnosis Overview
    • Assessment Overview
    • Lung Function Assessments
    • Questionnaires
    • Allergy Assessments
    • Phenotyping
    • Bronchoscopy
    • Imaging
    • Occupational Asthma
  • Management
    • Overview
    • Asthma Education
      • About Severe Asthma
      • Asthma Pathophysiology
      • Medications Education
      • Self-Monitoring
      • Triggers
      • Review
    • Written Action Plans
    • Adherence
    • Inhaler Technique
    • Physical Activity & Exercise
    • Interdisciplinary Approach & Multidimensional Assessment
    • Referral
  • Medications
    • Overview
    • Relievers
    • Preventers / Controllers
    • Add-on Therapies
    • Monoclonal Antibodies
      • Travelling with Monoclonal Antibodies
    • Bronchial Thermoplasty
  • Co-Morbidities
    • Overview
    • Pulmonary & Upper Airways
      • Allergic & Non-Allergic Rhinitis
      • Chronic Rhinosinusitis
      • Dysfunctional Breathing
      • Vocal Cord Dysfunction
      • Chronic Obstructive Pulmonary Disease
      • Bronchiectasis
      • Obstructive Sleep Apnoea
    • Extra-Pulmonary
      • Obesity
      • Anxiety & Depression
      • Gastro-oesophageal Reflux Disease (GORD)
      • Osteoporosis
      • Cardiovascular Disease & Metabolic Disease
  • Living with Severe Asthma
    • Overview
    • Daily Symptom Burden
    • Mental & Emotional Health
    • Intimacy & Relationships
    • Self-Management Support
    • Medication Use & Costs
    • Experience of Care
    • Experience of Asthma Attacks
    • Prognosis
  • Establishing a Clinic
    • Overview
    • Set-up
    • Staffing & Multidisciplinary Team Approach
    • Facilities
    • Delivery Approach
    • Tailored Referrals
    • Evaluation
    • Opportunities for Training & Research
    • Barriers & Hurdles
  • Paediatrics
    • Overview
    • Management in Paediatrics
    • Assessment in Paediatrics
    • Alternative Diagnosis & Co-Morbidities in Paediatrics
    • Psychosocial Issues in Paediatrics
    • Medications in Paediatrics
    • Asthma in the Adolescent Population
  • Resources
    • Overview
    • Clinic Recommendations
    • Infographics
    • Asthma Assessment Resources
    • Systematic & Multidimensional Assessment Resources
      • Airway Components
      • Comorbidity Components
      • Risk Factor Components
    • Translation & Implementation
    • Case Studies
    • Presentations
    • Videos
    • Relevant Links
    • Key References

Gastro-oesophageal Reflux Disease (GORD)

Home Co-Morbidities Extra-Pulmonary Gastro-oesophageal Reflux Disease (GORD)

Gastro-oesophageal reflux disease (GORD) is defined as symptoms or complications relating to reflux of stomach contents into the oesophagus. Most patients experience dyspepsia such as heartburn, but a proportion of patients are asymptomatic (Hopper 2015).

Prevalence

GORD is common in asthma, and particularly so in people with severe asthma, with reported prevalence rates from 17-74% (Heaney et al. 2010, Moore et al. 2010, Schleich et al. 2014, Shaw et al. 2015). A proportion of patients may also have silent reflux without any symptoms, such as heartburn (Harding 2003).

Impact

GORD is associated with poor symptom control (Liang et al. 2013) and has furthermore been identified as a risk factor for exacerbations in people with severe asthma (ten Brinke et al. 2005, Denlinger et al. 2017). Reflux may also trigger VCD, and induce symptoms relating to laryngeal dysfunction, which may mimic asthma symptoms. For more information see Vocal Cord Dysfunction

Conversely, asthma medications may induce or aggravate GORD, thus creating a potential vicious circle (Sweeney et al. 2016).

Proposed mechanisms of how GORD may trigger asthma are micro-aspiration, acid stimulation of the oesophagus and vagal nerve stimulation, although evidence is somewhat conflicting (Ayres et al. 1996).

GORD Impact infographic, gastrooesophageal reflux disease

Assessment

The diagnosis of GORD may be difficult as both pH monitoring and endoscopy have limited sensitivity (Naik et al. 2015). Hence, a trial of treatment with PPI is recommended as the initial diagnostic step in symptomatic patients (Naik et al. 2015).

The effect of treating GORD on asthma related outcomes is controversial.  While there is no convincing effect on objective outcomes such as lung function and airway hyperresponsiveness, some studies show effect on symptoms, quality of life and exacerbations (Gibson et al. 2003, Kiljander et al. 2013). This may suggest that symptoms triggered by GORD mimic asthma symptoms, rather than exacerbating airway inflammation or airway hyperresponsiveness. There are no predictors of the effect of treating GORD in the individual patient (Gibson et al. 2003). Acid suppression should be considered in patients with significant symptoms of GORD, with careful monitoring of the effect, whereas asymptomatic patients are generally unlikely to benefit from a trial of acid suppression.

Previous
Next

Last Updated on February 12, 2019

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

More results...

  • Overview
  • Pulmonary & Upper Airways
    • Allergic & Non-Allergic Rhinitis
    • Chronic Rhinosinusitis
    • Dysfunctional Breathing
    • Vocal Cord Dysfunction
    • Chronic Obstructive Pulmonary Disease
    • Bronchiectasis
    • Obstructive Sleep Apnoea
  • Extra-Pulmonary
    • Obesity
    • Anxiety & Depression
    • Gastro-oesophageal Reflux Disease (GORD)
    • Osteoporosis
    • Cardiovascular Disease & Metabolic Disease
For considerations relevant to the paediatric and adolescent population, please see Alternative Diagnoses & Co-Morbidities in Paediatrics or Asthma in the Adolescent Population

We want to know who accesses the Severe Asthma Toolkit and how it is used. Please complete our survey.

Responses will inform the continued development of the Severe Asthma Toolkit and future translation and implementation activities. Any feedback you provide will be greatly appreciated.

Complete Survey

  • Website Terms of Use
  • Website Survey
© Copyright 2018    CRICOS Provider Number 00109J    The University of Newcastle, Australia